On Tuesday, Viridian Therapeutics Inc (NASDAQ: VRDN) opened higher 3.51% from the last session, before settling in for the closing price of $13.98. Price fluctuations for VRDN have ranged from $9.90 to $27.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 31.28% over the last five years. Company’s average yearly earnings per share was noted -8.15% at the time writing. With a float of $73.61 million, this company’s outstanding shares have now reached $81.59 million.
The firm has a total of 143 workers. Let’s measure their productivity. In terms of profitability, gross margin is -1858.28%, operating margin of -111591.06%, and the pretax margin is -102092.38%.
Viridian Therapeutics Inc (VRDN) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Viridian Therapeutics Inc is 9.78%, while institutional ownership is 103.36%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -8.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.32% during the next five years compared to 31.28% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Check out the current performance indicators for Viridian Therapeutics Inc (VRDN). In the past quarter, the stock posted a quick ratio of 19.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3935.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.05, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.80 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Analysing the last 5-days average volume posted by the [Viridian Therapeutics Inc, VRDN], we can find that recorded value of 0.72 million was lower than the volume posted last year of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 18.78%.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 47.90%, which indicates a significant increase from 25.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.64% in the past 14 days, which was lower than the 55.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.91, while its 200-day Moving Average is $17.77. Now, the first resistance to watch is $14.97. This is followed by the second major resistance level at $15.48. The third major resistance level sits at $16.04. If the price goes on to break the first support level at $13.90, it is likely to go to the next support level at $13.34. Should the price break the second support level, the third support level stands at $12.83.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
There are currently 81,592K shares outstanding in the company with a market cap of 1.18 billion. Presently, the company’s annual sales total 300 K according to its annual income of -269,950 K. Last quarter, the company’s sales amounted to 70 K and its income totaled -86,910 K.
